Candidates for intensive local treatment in cIIIA-N2 NSCLC: Impact of mediastinal nodal extent and appearance.
Hidehito Horinouchi(Tokyo National Hospital), Tomohide Tamura(St. Luke's International Hospital), Hiroshi Nokihara(Tokushima University Hospital), Noboru Yamamoto(Tokyo National Hospital), Minako Sumi(Tokyo Metropolitan Geriatric Hospital), Ayako Tanaka, Shintaro Kanda(Shinshu University Hospital), Satoru Kitazono(The Cancer Institute Hospital), Yutaka Fujiwara(Aichi Cancer Center), Hirofumi Utsumi, Kuniko Sunami(Tokyo National Hospital), Tomoyasu Mimori, Hidenori Mizugaki(Hokkaido University)
Cited by 0
Related Papers
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|365